41.95

1.55% -0.66

Celldex Therapeutics Inc (CLDX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Celldex Therapeutics Inc stock is traded at $41.95, with a volume of 849.36K. It is down -1.55% in the last 24 hours and up +9.90% over the past month. Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Previous Close:

$42.61

Open:

$42.23

24h Volume:

849.36K

Relative Volume:

0.84

Market Cap:

$3.29B

Revenue:

$866.00K

Net Income/Loss:

$-283.65M

P/E Ratio:

-9.8313

EPS:

-4.267

Net Cash Flow:

$-226.25M

1W Performance:

+0.58%

1M Performance:

+9.90%

6M Performance:

+82.39%

1Y Performance:

+68.20%

1-Day Range:

$40.88

$42.34

1-Week Range:

$40.88

$45.14

52-Week Range:

$20.37

$45.14

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name

Celldex Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

908-200-7500

Address

53 FRONTAGE ROAD, HAMPTON

Employee

198

Twitter

@search?q=celldex

Next Earnings Date

2026-08-06

Latest SEC Filings

CLDX's Discussions on Twitter

Compare CLDX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLDX Celldex Therapeutics Inc	41.95	3.52B	866.00K	-283.65M	-226.25M	-4.267
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-20-26	Upgrade	Barclays	Underweight → Overweight
Mar-23-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Oct-21-25	Initiated	Mizuho	Outperform
Oct-13-25	Initiated	Barclays	Underweight
Apr-28-25	Initiated	Canaccord Genuity	Buy
Mar-20-25	Initiated	Morgan Stanley	Overweight
Feb-13-25	Initiated	UBS	Buy
Oct-07-24	Initiated	Citigroup	Buy
Sep-30-24	Initiated	Goldman	Neutral
Sep-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-18-24	Initiated	Stifel	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Dec-20-23	Initiated	TD Cowen	Outperform
Nov-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Aug-22-23	Initiated	Wells Fargo	Underweight
Sep-17-21	Initiated	Jefferies	Buy
Sep-10-21	Initiated	SVB Leerink	Outperform
Jul-22-21	Initiated	Guggenheim	Buy
Feb-21-20	Initiated	Cantor Fitzgerald	Overweight
Aug-01-17	Resumed	H.C. Wainwright	Buy
Nov-07-16	Initiated	Aegis Capital	Buy
Mar-08-16	Downgrade	Jefferies	Buy → Hold
Mar-07-16	Downgrade	Guggenheim	Buy → Neutral
Mar-07-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
Mar-07-16	Downgrade	Wedbush	Outperform → Neutral
Mar-01-16	Initiated	H.C. Wainwright	Buy
Aug-11-15	Reiterated	Brean Capital	Buy
Aug-11-15	Reiterated	Oppenheimer	Outperform
Aug-11-15	Reiterated	ROTH Capital	Buy
Jun-02-15	Reiterated	WBB Securities	Strong Buy
Nov-17-14	Reiterated	ROTH Capital	Buy
Mar-04-14	Reiterated	Oppenheimer	Outperform
Jul-08-13	Reiterated	Cantor Fitzgerald	Buy
Mar-08-13	Reiterated	Cantor Fitzgerald	Buy
Feb-26-13	Reiterated	Oppenheimer	Outperform
Jan-10-13	Reiterated	Cantor Fitzgerald	Buy
Oct-02-12	Reiterated	Oppenheimer	Outperform
Sep-14-12	Reiterated	Cantor Fitzgerald	Buy

View All

Celldex Therapeutics Inc Stock (CLDX) Latest News

Aug 14, 2026

Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake - Stock Titan

Aug 14, 2026

T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G - Stock Titan

Aug 14, 2026

Aug 12, 2026

Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX - MarketBeat

Aug 12, 2026

Aug 11, 2026

Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress - Sahm

Aug 11, 2026

HC Wainwright Issues Optimistic Forecast for CLDX Earnings - MarketBeat

Aug 11, 2026

Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat

Aug 11, 2026

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year HighTime to Buy? - MarketBeat

Aug 11, 2026

Aug 10, 2026

Assenagon Asset Management S.A. Buys 642,171 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat

Aug 10, 2026

Aug 09, 2026

Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results - Yahoo Finance

Aug 09, 2026

Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern? - Yahoo Finance

Aug 09, 2026

Aug 08, 2026

Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return - Yahoo Finance UK

Aug 08, 2026

What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update? - Yahoo Finance

Aug 08, 2026

First Trust Advisors LP Has $2.17 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat

Aug 08, 2026

Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat

Aug 08, 2026

Aug 07, 2026

Morgan Stanley Boosts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $46.00 - MarketBeat

Aug 07, 2026